July 13, 2022

July 13, 2022

The FDA Authorizes Pharmacists to Prescribe Paxlovid to Eligible Patients Who Test Positive for COVID-19

This is part of a concerted effort to make sure all those with a high risk for progression to a severe case of COVID-19 have quick and easy access to appropriate therapy. In addition, since Paxlovid therapy should be started within five days of the infection, this change should

July 13, 2022

Spontaneous Remission of Chronic Lymphocytic Leukemia in a Patient with SARS-CoV-2

This should not be part of anyone’s game plan. Still, it was nice to read that for at least this one 67-year-old asymptomatic CLL patient, a case of COVID-19 associated with low blood counts and a broad spectrum of treatments resulted in his CLL becoming undetectable in his bone

July 13, 2022

ASH 2021 – Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) After Progression on I Alone (V-naïve) or After Progression on Sequential I and V (Double Refractory)

Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) After Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double Refractory)

July 13, 2022

ASH 2021: Dr. John Seymour on Acquired Mutations in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) After Fixed-Duration Venetoclax-Rituximab Treatment

We discussed an analysis of acquired mutations in patients from the MURANO trial whose disease had progressed.

July 13, 2022

ASH 2021: Dr. Deborah Stephens on Early Intervention vs. Delayed Therapy with Venetoclax plus Obinutuzumab for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

We discussed an ongoing clinical trial currently recruiting patients to see if early intervention with venetoclax plus obinutuzumab can produce better outcomes for high-risk patients compared with traditional delayed therapy.

July 13, 2022

ASH 2021: Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (R/R CLL/SLL)

Dr. Matthew Davids and colleagues presented this research at the American Society for Hematology annual meeting held in December 2021 (ASH 2021).

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

July 13, 2022

The FDA Authorizes Pharmacists to Prescribe Paxlovid to Eligible Patients Who Test Positive for COVID-19

Spontaneous Remission of Chronic Lymphocytic Leukemia in a Patient with SARS-CoV-2

ASH 2021 – Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) After Progression on I Alone (V-naïve) or After Progression on Sequential I and V (Double Refractory)

ASH 2021: Dr. John Seymour on Acquired Mutations in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) After Fixed-Duration Venetoclax-Rituximab Treatment

ASH 2021: Dr. Deborah Stephens on Early Intervention vs. Delayed Therapy with Venetoclax plus Obinutuzumab for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

ASH 2021: Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (R/R CLL/SLL)

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT